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Abstract 
Background: Only drafts of regulatory guidelines for the registration of biosimilars are available in Lebanon. We 
analyzed the results of a regional survey conducted in Lebanon to understand the impact of different parameters on 
the acceptance and future prescription of biosimilars. We also reviewed the current situation of biosimilars around the 
world. The study surveyed healthcare professionals from the Arab countries, Iran, Belgium and Italy. Data about the 
participants’ specialty, country of residence, their knowledge about biosimilars, biosimilars’ prescription, price influ‑
ence and the manufacturer’s credibility were collected.
Results: 117 questionnaires were completed and returned: 46 (39.3%) respondents were oncologists. 72 (61.5%) 
respondents were Lebanese, and the others from Egypt, Syria, Algeria, Iraq, Sudan, Jordan, Iran, Belgium and Italy. 
77 (65.8%) respondents had knowledge about biosimilars, of whom 48 (62.3%) considered biosimilars as biologics 
that demonstrate bioequivalence with the original biodrug and have all preclinical and clinical trials equal to those 
already performed with the original biodrug. 74 (63.2%) out of 117 respondents agreed that biosimilars in the Arab 
and Middle Eastern market are already marketed. Among the 48 participants who prescribe biosimilars, the main 
prescription driver was the drug’s approval by the FDA and EMA (68.8%). 71 (60.7%) respondents considered that the 
main advantage of biosimilars is their lower price and 41 (35%) out of the 117 respondents declared that they should 
know in which country the drug has been tested/created before using it in their own country. 35% of the respond‑
ents thought that the cost of a treatment should not come before its effectiveness or safety/tolerance, given that the 
biosimilar will be less expensive than the reference drug.
Conclusions: Biosimilars’ acceptance and use is increasing worldwide. Only few physicians are aware of biosimilars 
presence in the market and do prescribe them in Lebanon and the Arab region. This could be mainly explained by 
lack of confidence in efficacy, safety, manufacturing process and price of these products, and lack of clear legislation. 
Thus, WHO is finalizing a new guideline for similar biotherapeutic agents. This could be a starting point for the Leba‑
nese government to support the authorization of biosimilars.
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Background
Introduced into the market more than 30  years ago, 
biological products result from biologic material and 
encompass a wide range of elements such as hormones, 
vaccines, antibodies, proteins, polysaccharides, polynu-
cleotides, growth factors, blood products, and live viral 
material; they differ greatly from chemical medicines 
(Liang and Mackey 2012). Biosimilars are medicinal 
products with a similar but not identical safety, efficacy 
and quality as the authorized reference (originator) bio-
logic agents. They are composed of an analogous active 
substance but are large molecular-weight, complex mol-
ecules that are produced in living cells through genetic 
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engineering (Sylvester et al. 2013). They are also referred 
to as biological and biotherapeutic agents/products.
The Biologics Price Competition and Innovation Act 
(BPCIA) defines biosimilar as a biological product highly 
similar to the reference product notwithstanding minor 
differences in clinically inactive components; and with 
no clinically meaningful differences between the biologic 
product and the reference product in terms of the safety, 
purity, and potency of the product (FDA 2009).
In this paper, we report the results of a regional survey 
to understand the impact of different parameters on the 
acceptance and future prescription of biosimilars in the 
Lebanese and Arab markets. We also analyze the cur-
rent situation in the region and discuss the worldwide 
situation of biosimilars focusing mainly on the European 
Union (EU) and the United States (U.S.) laws, regulations 
and legislation pathways, pricing and challenging market 
access.
Methods
A regional survey was conducted from 26 to 28 March 
2015 during the Pan Arab Oncology Meeting in Bei-
rut, Lebanon. The meeting drew over 150 participants 
from the Arab countries, Iran, Belgium and Italy. It was 
attended by a wide range of healthcare professionals: 
oncologists, hematologists, hemato-oncologists, gynecol-
ogist, surgeons, pulmonologists, radiologists, anatomo-
pathologists, pharmacists and others.
A two-page questionnaire of 14 questions was dis-
tributed to all the meeting participants. The survey tool 
collected data about the participants’ specialty, country 
of residence, their knowledge about biosimilars, bio-
similars’ prescription, price influence and the manufac-
turer’s credibility (Additional file 1). Data collected were 
described with frequencies and percentages using the 
SPSS software application (IBM Corp. Released 2014. 
IBM SPSS Statistics for Windows, Version 23.0. Armonk, 
NY: IBM Corp).
Results
In total, 117 questionnaires were completed and 
returned. The results of the survey showed that 46 
(39.3%) respondents were oncologists, 17 (14.5%) were 
hemato-oncologists and 14 (12%) were nurses while 
only 2 (1.7%) were hematologists. The majority of the 
respondents were Lebanese (61.5%, n  =  72), 12% were 
from Egypt, 11.1% from Syria and the others from Alge-
ria, Iraq, Sudan, Jordan, Iran, Belgium and Italy (Table 1).
Moreover, 77 (65.8%) out of the 117 respond-
ents had knowledge about biosimilars. Among the 77 
respondents who seemed to have a good understand-
ing of scientific issues pertaining biosimilars, 48 (62.3%) 
respondents considered biosimilars as biologics that 
demonstrate bioequivalence with the original biod-
rug and have all preclinical and clinical trials equal to 
those already performed with the original biodrug. 
Besides, when approved, they already have a well-defined 
immunogenicity.
As for biosimilars’ prescription, 74 (63.2%) out of 117 
respondents agreed that biosimilars in the Arab and Mid-
dle Eastern market are already marketed. In parallel, 53 
(45.3%) respondents agreed that biosimilars are being 
manufactured in the same region. In addition, 48 (41%) 
respondents confirmed that they prescribe biosimilars 
versus 38 (32.5%) who do not prescribe them. Among 
the 48 participants who prescribe biosimilars, the main 
driver for prescribing them was the drug’s approval by 
the Food and Drug Administration (FDA) and the Euro-
pean Medicines Agency (EMA) (68.8%), followed by 
a lower price of the bioequivalence in comparison with 
the innovator (64.6%), then bioefficacy (47.9%), safety 
(41.7%), good manufacturing practices and high reputa-
tion of the manufacturer (31.3%).
As for the price influence, 35% of the respondents 
thought that the cost of a treatment should not come 
before its effectiveness or safety/tolerance, given that 
the biosimilar will be less expensive than the reference 




 Oncology 46 (39.3)
 Hemato‑oncology 17 (14.5)
 Nurse 14 (12.0)
 Surgery 10 (8.5)
 Gynecology 6 (5.1)
 Pharmacy 6 (5.1)
 Urology 5 (4.3)
 Radiology 3 (2.6)
 Hematology 2 (1.7)
 Anatomopathology 1 (0.9)
 Other 7 (6.0)
Country of residence
 Lebanon 72 (61.5)
 Egypt 14 (12.0)
 Syria 13 (11.1)
 Algeria 8 (6.8)
 Iraq 3 (2.6)
 Belgium 2 (1.7)
 Sudan 2 (1.7)
 Jordan 1 (0.9)
 Iran 1 (0.9)
 Italy 1 (0.9)
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drug. In contrast, 25.6% thought that the lower prices 
of the biosimilar are a good news because patients will 
be treated with biologics, and would help cost savings 
(26.5%).
The results also showed that physicians would mainly 
trust a company highly experienced in manufacturing 
small-molecule generic drugs as a producer of biosimilars 
(48.7%), knowing that they have the expertise to deal with 
regulatory authorities and have the knowledge of approv-
al’s guidelines. Interestingly, physicians will trust more a 
company with prior experience in manufacturing biolog-
ics as a manufacturer of biosimilars (54.7%) (Table 2).
Discussion
Our survey marks the acceptance of physicians to a bio-
similar submitted and responding to EMA and FDA reg-
ulations. Our finding complies with international results 
where PubMed-indexed manuscripts and grey literature 
reported the acceptance of prescribing FDA-approved 
biosimilars by almost all physicians surveyed. These phy-
sicians also believe that the FDA-approved biosimilars 
have the same efficacy (effectiveness) and safety profile as 
the originator biological (Felix et al. 2014).
Pricing is still a key factor and cost saving also seemed 
to be an important driver for prescribing biosimilars 
(26.5%). We note that some biosimilars are marketed at 
a reduced price, compared to the innovator. Such low 
price can only be explained by a trivial investigational 
cost, thus the absence of adequate comparative studies. 
Consequently, efficacy and safety of such drugs are ques-
tionable. EMA and FDA commonly reject these drugs 
for lack of scientific criteria of safety. Recognition and 
authorization from legal entities is crucial for physicians, 
to encourage them to prescribe biosimilars, but what 
will influence the prescriber? Is it patients, fellows or the 
health system? In fact, the major factor influencing the 
prescriber is the payer. This is the case in organizations 
where the health authorities can force the prescriber, and 
where the substitution of the innovator is applied. Thus, 
this proves the doubt in biosimilars efficacy and safety by 
physicians in addition to the unwillingness to prescribe 
biosimilars unless mandatory. Ultimately, the credibility 
of the biosimilar is the main driver for the launch of any 
biosimilar in the Arab world. While literature reports that 
the manufacturers may use higher rebates on originator 
biologicals as a barrier to adopting biosimilars (Felix et al. 
2014), we aim to investigate in future surveys what pre-
scribing behavior would have changed had the price lev-
els been specifically examined. Also, our next survey will 
focus on understanding how Lebanese and Arab health 
care professionals perceive an adequate level of “trust” in 
the medication, namely how much a discount makes this 
affordable and testing whether prescribers are aware of 
the pricing/payor factors in their own regions as regards 
to biosimilars.
In the following sections, we summarize the main 
points about the biosimilars’ regulations and challenging 




The U.S., EU, Japan, Canada and the pharmerging mar-
kets (China, India, Brazil and Mexico) form geographi-
cally the market for biologics and biosimilars. Each of 
these markets has its own regulations and laws concern-
ing biosimilars. EU has led the way in developing a legal 
framework for the approval of biosimilar products via 
EMA.
As for the U.S., several conditions make the US as the 
biggest opportunity for biosimilars to extremely progress 
by 2020 such as the presence of competing and leading 
manufacturers (Pfizer and Merck), patients and health 
insurers needing the access to low-cost, high-value 
drugs. Thus, this opportunity will be the cut-off point for 
the success or failure of biosimilars in the next decade 
(Kresse 2009; IMS Health 2011).
EU guidelines EMA is held accountable for the scien-
tific assessment of medicines for use in EU countries, and 
for the approval of all medicines for human and animal 
use derived from biotechnology and other high-tech pro-
cesses including biosimilars. Those guidelines concerning 
biosimilars’ requirements for the market approval have 
been dictated by the EMA in accordance with the funds of 
the Community Code. They enclose the following: (1) the 
original product must be authorized within the EU, (2) the 
8 years data exclusivity of the reference must be expired, 
(3) the similarity between the safety, efficacy and quality of 
the biosimilar and the original biologic product must have 
been demonstrated, (4) the primary amino acid arrange-
ment of the biosimilar protein has to be matching to the 
reference product amino acid sequence, (5) the biosimilar 
manufacturer needs to validate each step of development, 
comparative but possibly abbreviated non-clinical phar-
macology and toxicology studies, human Pharmacokinet-
ics (PK) and Pharmacodynamics (PD) studies and human 
efficacy and safety studies including immunogenicity, 
and (6) the Risk Management Plan must include pharma-
covigilance (IMS Health 2011; Church et al. 2009; Choy 
and Jacobs 2014).
Since October 2006 till present, EMA has approved 21 
biosimilars corresponding to 8 active molecules, in six 
categories of biologics (epoetins, filgrastims, follitropins, 
growth hormones, insulins, and monoclonal antibodies) 
(European Medicines Agency 2016) (Table 3).
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Table 2 Knowledge about biosimilars and their prescription (n = 117)
Questionnaire item N (%) N (%)
Knowledge about biosimilars
 Do you know what biosimilars are?
  Yes 77 (65.8)
  No 14 (12.0)
  No answer 26 (22.2)
 Choose one item that adjusts to your concept of biosmilarsa
  A biologic that demonstrates bioequivalence with the original biodrug and has all preclinical and clinical trials equal 
to those already performed with the original biodrug. Besides, when approved, it already has a well‑defined immu‑
nogenicity
48/77 (62.3)
  A biologic that demonstrates bioequivalence with an original biodrug and does not need clinical trials to be com‑
mercialized
12/77 (15.6)
  A molecule equal to that of the original biologic but of lower production cost 17/77 (22.1)
  An attempt to copy an innovative biodrug and will never be equal to it 1/77 (1.3)
  A generic biologic of an already commercialized biodrug 4/77 (5.2)
Biosimilars’ prescription
 Do you agree with the information that there are already marketed biosimilars in the Arab and Middle Eastern Market?
  Yes 74 (63.2)
  No 22 (18.8)
  No answer 21 (17.9)
 Do you agree with the information that biosimilars are being manufactured in the Arab and Middle Eastern Market?
  Yes 53 (45.3)
  No 38 (32.5)
  No answer 26 (22.2)
 Do you prescribe biosimilars?
  Yes 48 (41.0)
  No 38 (32.5)
  No answer 31 (26.5)
 What are the major drivers that encourage you to prescribe biosimilars?
  Safety 20/48 (41.7)b 40/117 (34.2)c
  Bioefficacy 23/48 (47.9)b 45/117 (38.5)c
  FDA and EMA approval for biosimilar 33/48 (68.8)b 61/117 (52.1)c
  Good manufacturing practices and high reputation of the manufacturer 15/48 (31.3)b 31/117 (26.5)c
  Country of origin of the biosimilars’ manufacturer 14/48 (29.2)b 25/117 (21.4)c
  Lower price of the bioequivalence in comparison with the innovator 31/48 (64.6)b 58/117 (49.6)c
  Nothing encourages you 2/48 (4.2)b 6/117 (5.1)c
 What are the major local drivers that encourage you to prescribe biosimilars?
  Assurance that phase III clinical trials will be performed in a sample of the local population 14/48 (29.2)b 33/117 (28.2)c
  Maintenance of an adequate national system of pharmacovigilance specific to biosimilars 23/48 (47.9)b 36/117 (30.8)c
  Transparency of the local health regulatory authority(ies) 16/48 (33.3)b 34/117 (29.1)c
  Nothing encourages you 7/48 (14.6)b 14/117 (12.0)c
 In your opinion, what are the advantages of a biosimilar?
  Lower price 71/117 (60.7)
  Commercialization approved with initial indication including all diseases previously approved for the innovative 
biodrug
32/117 (27.4)
  Administration route different from that of the original biodrug 10/117 (8.5)
  Lower therapeutic dose 8/117 (6.8)
  There are no advantages 6/117 (5.1)
 Now that biosimilars are coming to the market, you think thatd
  Patient associations should be informed and should be able to give their opinion 28/117 (23.9)
  Patients should systematically be given information 28/117 (23.9)
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Moreover, substitutability and interchangeability differ 
from a country to another in the EU, each having imple-
mented its own legislation. For instance, France and Italy 
exclude substitution of innovative biologics by biosimi-
lars, United Kingdom (UK) restricts these substitutions. 
Hence, the European biopharmaceutical industries are 
asking for demonstration and a clear differentiation of 
the concepts of similarity and interchangeability (IMS 
Health 2011).
U.S. guidelines Since 2006, the FDA has approved bio-
logical products based on comparability such as Omni-
trope, Enoxatrapine and Genotropin. It is only in 2010, 
after obtaining the Patient Protection and Affordable Care 
(PPAC) Act signed by President Obama, that the US had 
the authority to approve biosimilars (FDA 2010). The 2009 
BPCIA formally passed under the PPAC Act, an amend-
ment of the Public Health Service Act (PHS Act) reduced 
approval pathway for biological agents that showed to be 
greatly similar (biosimilar) to a FDA approved biological 
product. The BPCIA is theoretically comparable to the 
Drug Price Competition and Patent Term Restoration Act 
of 1984 that created biological drug approval through the 
Federal Food, Drug, and Cosmetic Act (FFD&C Act). The 
BPCIA supports the FDA’s long-lasting policy that allows 
adequate trust on the known information about a drug, 
thus saving time, resources and avoiding the repetition of 
already available human or animal tests (Nick 2012).
Another important part of the amendment in the 
PPAC Act for biosimilars is the exclusivity of the data. 
Data exclusivity is the time frame between biosimilar fill-
ing on the innovator data. It is designed to protect the 
innovation taking into consideration the time-consum-
ing, expensive and uncertain process involved during the 
waiting period of the innovator to gain the FDA approval. 
The data exclusivity time ranges between 12 and 14 years 
(US Code 2012).
In April 2015, the FDA released 2 highly-anticipated 
guidances on biosimilars. The first guidance “Scien-
tific Considerations in Demonstrating Biosimilarity to a 
Reference Product” assists companies in demonstrating 
that a proposed therapeutic protein product is biosimi-
lar to a reference product for the purpose of submit-
ting an application, called a “351(k)” application, to the 
FDA. It also describes a risk-based “totality-of-the-evi-
dence” approach that the FDA intends to use to evalu-
ate the data and information submitted in support of a 
determination of biosimilarity of the proposed product 
Table 2 continued
Questionnaire item N (%) N (%)
  We should wait for many patients to receive biosimilars in a real life setting before recommending its use in a large 
population of patients
16/117 (13.7)
  We should know in which country the drug has been tested/created before using it in your own country 41/117 (35.0)
Price influence
 The biosimilar will be less expensive than the reference drug, you think thatd
  These are good news because more patients will be treated with biologics 30/117 (25.6)
  The cost of a treatment should not come before its effectiveness or safety/tolerance 41/117 (35.0)
  This will help cost savings 31/117 (26.5)
  If biosimilars are already in the market, a 30% reduction from the innovator’s price will be sufficient 15/117 (12.8)
  You do not think that a lower cost will change something 4/117 (3.4)
Manufacturers’ credibility
 Do you trust a company highly experienced in manufacturing small‑molecule generic drugs as a producer of biosimilars knowing that they have 
the expertise to deal with regulatory authorities and have the knowledge of approval’s guidelines?
  Yes 57 (48.7)
  No 19 (16.2)
  No answer 41 (35.0)
 Do you trust a company with prior experience in manufacturing biologics as a manufacturer of biosimilars?
  Yes 64 (54.7)
  No 13 (11.1)
  No answer 40 (34.2)
a Some people who said no to knowledge also answered this question which is not correct since it says in the questionnaire that only those who said yes in the prior 
question should answer these questions. Those people who answered but they should have not were not included in this table. For those eligible to answer, they 
should choose one answer but some of them did more than one question (hence the overall % will exceed 100%)
b Answers among respondents who answered yes to prescribing biosimilars
c Answers among all respondents
d Participants were supposed to pick only one answer but they did not
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to the reference product (U.S. Department of Health 
and Human Services et al. 2015a). The second guidance 
entitled “Quality Considerations in Demonstrating Bio-
similarity to a Reference Protein Product” provides an 
overview of analytical factors to consider when assess-
ing biosimilarity between a proposed therapeutic pro-
tein product and a reference product for the purpose 
of submitting a 351(k) application. This includes the 
importance of extensive analytical, physico-chemical 
and biological characterization in demonstrating that 
the proposed biosimilar product is highly similar to the 
reference product notwithstanding minor differences 
in clinically inactive components (U.S. Department of 
Health and Human Services et  al. 2015b). Also in May 
2015, the FDA released a draft guidance on “Biosimilars: 
Questions and Answers Regarding Implementation of 
the Biologics Price Competition and Innovation Act of 
2009”. This guidance document is being distributed for 
comment purposes only and provides answers to com-
mon questions from people interested in developing 
biosimilar products. The question and answer format 
addresses questions that may arise in the early stages 
of product development, such as how to request meet-
ings with the FDA, addressing differences in formulation 
from the reference product, how to request exclusivity, 
and other topics (U.S. Department of Health and Human 
Services et al. 2016).
As of 05 October 2016, the FDA authorized 4 biosimi-
lars (Table 4).
Pricing and challenging market access
Biosimilars’ sales are projected to reach around $25–$35 
billion by 2020. Since the first biosimilar approval in EU 
in 2006, 21 biosimilars are now authorized by the EMA 
(European Medicines Agency 2016) (Table 3), 4 biosimi-
lars by the FDA (Table 4), and 250 biosimilars are in the 
pipeline globally (Deloitte 2015). This market is growing 
tremendously in spite of the effort to reduce the global 
healthcare costs, which is making it the fastest rising 
market of all biologics sector in the next 5  years (IMS 
Health 2011).
This increase in spending was estimated to 700% 
between 2010 and 2015, summing up to approximately 
$80 billion in global sales to replace branded biologic 
agents losing their patent by 2015 (Liang and Mackey 
2012). Consequently, switching to biosimilars would help 
in saving billions of dollars annually. This is expected 
to reach $40–$250 billion in the coming 10 years in the 
U.S. alone (Deloitte 2015). However, the expected suc-
cess and progress of biosimilars in Europe is higher than 
the US markets due to the presence of general and spe-
cific guidelines. Other factors such as comparability 
studies (quality, efficacy and safety), substitution, pric-
ing and reimbursement may affect biosimilars market 
Table 3 EMA approved biosimilars (European Medicines Agency 2016)
Date of biosimilar EMA approval Biosimilar product Original product Active substance
12 April 2006 Omnitrope Genotropin Somatropin
28 August 2007 Abseamed Epogen/Eprex Epoetin alfa
28 August 2007 Binocrit Epogen/Eprex Epoetin alfa
28 August 2007 Epoetin Alfa Hexal Epogen/Eprex Epoetin alfa
18 December 2007 Silapo Epogen/Eprex Epoetin zeta
18 December 2007 Retacrit Epogen/Eprex Epoetin zeta
15 September 2008 Biograstim Neupogen Filgrastim
15 September 2008 Ratiograstim Neupogen Filgrastim
15 September 2008 Tevagrastim Neupogen Filgrastim
06 February 2009 Filgrastim Hexal Neupogen Filgrastim
06 February 2009 Zarzio Neupogen Filgrastim
08 June 2010 Nivestim Neupogen Filgrastim
10 September 2013 Inflectra Remicade Infliximab
27 September 2013 Ovaleap Gonal‑f Follitropin alfa
10 October 2013 Remsima Remicade Infliximab
18 October 2013 Grastofil Neupogen Filgrastim
27 March 2014 Bemfola Gonal‑f Follitropin alfa
09 September 2014 Abasaglar (previously Abasria) Lantus Insulin glargine
18 September 2014 Accofil Neupogen Filgrastim
14 January 2016 Benepali Enbrel Etanercept
26 May 2016 Flixabi Remicade Infliximab
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accessibility (Simoens et al. 2011). Thus, we assume that 
switching to biosimilars does not consider “biobetter” 
prescribing, where a better biologic will still be priced 
higher, and prescribers will likely lean toward the more 
effective biologic.
Moreover, due to the high research and developmen-
tal cost of biosimilars, the difference of prices between 
them and the reference biological agent is supposed to 
be less compared to the reference and generics. In fact 
biosimilars are priced 30% less than the originator com-
pared to a reduction of 80% for the generics after the first 
6 months to years after its entry to the market. Although 
this reduction may not be significant but seems to be suf-
ficient to generate high profitable rates (Lockwood et al. 
2013).
However, the biosimilar market is not easy to access 
given the challenges in terms of regulatory uncertainty 
production complexity, interchangeability and competi-
tion. In particular, the lack of clear guidelines on inter-
changeability and substitutability with reference biologics 
will probably cause physicians to be more cautious in 
prescribing biosimilars until they gain comfort with the 
efficacy and quality of biosimilars (Deloitte 2015). These 
entry barriers for manufacturers should be crossed to 
penetrate a highly competitive platform, yet cost-effec-
tive. Thus, for a positive entry to the biosimilar mar-
ket, few major abilities should be accomplished such as 
adequate research and development capabilities, specific 
biomanufacturing platforms, legal expertise and interna-
tional distribution channels, global network of marketing 
sales and a robust lobbying with regulatory organiza-
tions, opinion leaders, governments and key people to 
facilitate the approval of laws and regulations (Calo-Fer-
nandez and Martinez-Hurtado 2012).
Biosimilars in Lebanon
Indications and consumption
Lebanon’s healthcare sector is considered as one of the 
best in the Middle East and North Africa (MENA) region. 
Many biosimilars are being used, as in the global market, 
such as granulocyte colony stimulating factor (G-CSF) 
frequently prescribed in the hemato-oncology field. The 
list also includes erythropoietin given to patients with 
chronic renal failure or oncological ailments, Humira®, 
Remicade® and Enbrel® in rheumatoid arthritis, psoria-
sis, and other immunological diseases.
A 2006 report by the World Health Organization 
(WHO) about the Health System Profile in Leba-
non showed that the total health expenditure of Gross 
Domestic Products is about 12% (World Health Organi-
zation 2006). However, being expensive therapeutic 
drugs, biosimilars are not accessible for all Lebanese pop-
ulation. Hence, major imported oncological drugs to the 
Lebanese market were studied in terms of cost and con-
sumption to show their impact on total budget.
Guidelines: laws and regulations
To assure the biosafety and efficacy of biosimilars, the 
Lebanese Ministry of Public Health (MOPH) decided 
to develop requirements and guidance for registration 
of biosimilar drugs. Those were drafted in 2013 and fol-
low the EMA guidelines, WHO and International Con-
ference for Harmonization (ICH) Guidance on Similar 
Biological Products in collaboration with the French 
National Agency for Medicines and Health Products 
safety (Agence Nationale de Securité des Médicaments, 
ANSM) (CTD format) (Republic of Lebanon 2013). Con-
sequently, a special committee to propose amendments 
to the decree 571/2008 concerning the regulatory guide-
lines for biosimilar medicinal products in Lebanon was 
formed. While waiting for the committee approval and 
an update of legal texts, the approval of biosimilars fol-
lows same rules as generics. Neither the “Requirements 
for Drug Substance and Finished Product Checklist” nor 
the “Requirements for Bioequivalence Study Checklist” 
requested analysis specific to the biosimilars are present. 
Biosimilars, as separate category is not even mentioned 
for the time being.
The “General Regulatory and Manufacturing Rules” 
state in the decree 571 that “the international authorities 
Table 4 FDA approved biosimilars
Date of biosimilar FDA approval Biosimilar product Original product Active substance
06 March 2015 (U.S. Department of Health and Human Services and Food and Drug 
Administration 2016a)
Zarxio Neupogen Filgrastim
05 April 2016 (U.S. Department of Health and Human Services and Food and Drug 
Administration 2016b)
Inflectra Remicade Infliximab
30 August 2016 (U.S. Department of Health and Human Services and Food and Drug 
Administration 2016c)
Erelzi Enbrel Etanercept
23 September 2016 (U.S. Department of Health and Human Services and Food and Drug 
Administration 2016d)
Amjevita Humira Adalimumab
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that should be followed for approval of registration are 
the FDA, the American Medical Association (AMA) and 
WHO. The drug that will be approved should also be 
registered in at least 2 countries”. Based on the follow-
ing decision of the MOPH, prices are established based 
on the price in the country of origin with comparison to 
the established median price in many European countries 
such as France, UK, Belgium, Switzerland, Italy, Spain 
and Portugal. But nothing is mentioned concerning the 
pricing of biosimilars per se.
Challenges
Every country in the Arab world has a different health 
system and has its own laws concerning registration of 
new drugs. Drug patent, protecting brands and innova-
tors differ as well. For instance in Jordan, any generic can 
be introduced in the Jordanian market after 3  years of 
launching in the country where it was first approved (Jor-
dan Food and Drug Administration 2016), while in Leba-
non the drug’s patent follows the international guidelines. 
This difference can be explained by the fact that not all 
countries are member of the World Trade Organization 
(WTO).
With the approaching patent expiration of major biop-
harmaceutical products and the emerging growth of 
biosimilars in global markets, issues will arise due to the 
fact that biological products or biosimilars are different 
from the small generic drugs. Safety concerns will sur-
face again unless biosimilars prove to have a comparable 
safety profile. Alike other countries, prescriptions of bio-
similars in Lebanon and the Arab world will face many 
challenges, especially the patient and physician’s trust in 
the medication per se, the affordability, accessibility and 
availability issues.
Conclusions
Biosimilars’ acceptance and use is growing worldwide. 
Despite this accomplishment, only the EU via EMA and 
US FDA have dictated specific regulations and guidelines 
related to biosimilars. Only few physicians are aware of 
biosimilars presence in the market and do prescribe 
them. Further investigations must be carried out to find 
out whether this is ascribed to lack of confidence in effi-
cacy, safety, manufacturing process and price of these 
products. Lack of clear legislation is likely to be responsi-
ble for the low rate of awareness about biosimilars; thus, 
WHO is finalizing a new group of guidelines for similar 
biotherapeutic agents. This is intended to help national 
regulatory agencies, manufacturers, and other interested 
parties and could be a starting point for the Lebanese 
government to support the authorization of biosimilars.
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